Excitement as New AIDS Drugs Coming to the Forefront
I'll tell you whatâ€¦when I read scientific research papers and articles on new technologies and medical advancements, my mind immediately turns to a
mush-like substance that requires several read-throughs to get the general gist. Granted, I love reading about medical news, I really do, but on first
reads, I usually read an article and go, "Wait, what did I just read again?" Now, I mention all of this because I want to make sure I get all of the
following important information, gleaned from Science Daily, just perfect.
A possibility of an entire new set of AIDS drugs is on the horizon as University of Michigan researchers have created something that has not been
seen in over two decades: a means for inhibiting a target that is commonly used when treating those patients afflicted with HIV, particularily those who
have used condoms. The compound in question is the HIV protease, which most AIDS drugs aim for. This HIV protease is responsible for the actual
replication of HIV, according to the University of Michigan head researcher on this research and professor of medicinal chemistry, Heather Carlson.
Originally using computers to model the compound, further lab research demonstrated that the compound actually works in inhibiting this protease.
Carlson goes on to explain that this research is still in the preliminary stages since it is "easy to make an inhibitor, (but) it's very hard to make a drug.
This compound is too weak to work in the human body. The key is to find more compounds that will work by the same mechanism." What has
researchers on this study excited is the fact that while AIDS drugs currently on the market also weaken the HIV-1 protease to prevent HIV from
replicating, this compound does the same thing but in an entirely different way.
For further clarification, consider what happens when the HIV-1 protease is weakened. The AIDS drugs prevent the protease from creating the
proteins needed to gather and create an active virus. Current AIDS drugs